Código QR

Serum infliximab levels and clinical response in hidradenitis suppurativa

Abstract Background Infliximab (IFX) is a chimeric immunoglobulin G‐1κ monoclonal antibody that neutralises the biologic activity of tumour necrosis factor‐α, and has shown efficacy (off‐label) for the treatment of severe hidradenitis suppurativa (HS). The relationship between clinical response and...

Descrición completa

Gardado en:
Principais autores: Erwin Benassaia, Jean‐David Bouaziz, Marie Jachiet, Florence Cordoliani, Anne Saussine, Clemence Lepelletier, Lauriane Goldwirt, Charles Cassius, Adèle deMasson, Martine Bagot, Hervé Bachelez, Florence Assan
Formato: Artigo
Idioma:Inglês
Publicado: Wiley 2023-06-01
Series:JEADV Clinical Practice
Assuntos:
hidradenitis suppurativa
HiSCR
infliximab
therapeutic drug monitoring
trough serum infliximab
Acceso en liña:https://doi.org/10.1002/jvc2.139
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares